Celltrion

068270.KO

122.82 USD

-1.04

-0.84%

Overview

Last close

122.82 usd

Market cap

25.44B usd

52 week high

176.66 usd

52 week low

97.64 usd

Target price

177.21 usd

Valuation

P/E

N/A

Forward P/E

24.6305

Price/Sales

13.3986

Price/Book Value

2.1166

Enterprise Value

26.35B usd

EV/Revenue

12.7826

EV/EBITDA

48.1615

Key financials

Revenue TTM

1.91B usd

Gross Profit TTM

792.40M usd

EBITDA TTM

552.71M usd

Earnings per Share

N/A usd

Dividend

0.36 usd

Total assets

20,127.06B usd

Net debt

N/A usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.